Search - tctmd.com

Displaying 201 - 220 of 300

Sort: Relevancy | Date

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presenter: Laurent Bonello

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

Presentation TCT 2012

Platelet Reactivity, Genetics, and Thienopyridine Responsiveness: Theoretical and Real-world Implications

Presenter: Matthew Price

October 22, 2012

News Daily News

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

October 18, 2012

News Daily News

Study Supports Half-Dose Prasugrel for Low-Weight CAD Patients

October 18, 2012

Presentation

Reduction in Platelet Reactivity with Prasugrel 5 mg in Low-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Weight Patients

Presenter: David Erlinge

October 17, 2012

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

News Daily News

La Eficacia del Clopidogrel se Redujo en los Diabéticos tras sufrir un IM

September 07, 2012

News Daily News

Efficacy of Clopidogrel Diminished in Diabetics After MI

September 07, 2012

News Daily News

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

L.A. McKeown

August 20, 2012

News Daily News

La programación de pruebas de plaqueta es fundamental para la estrategia de clopidogrel después de una ICP por ACS

L.A. McKeown

August 20, 2012

News Daily News

PLATO Substudy: ‘Smoker’s Paradox’ Shows No Effect on Ticagrelor

August 03, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

Las Directrices Elevan el Ticagrelor a la Categoría de Antiplaquetario de 1ª Línea contra la Angina Inestable

Jason Kahn

July 17, 2012

News Daily News

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Jason Kahn

July 17, 2012

News Daily News

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

July 12, 2012

News Daily News

Meta Análisis: Ajustar el Tratamiento según la Función Plaquetaria Mejora los Resultados

July 12, 2012

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

July 10, 2012

Advertisement

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Platelet Reactivity, Genetics, and Thienopyridine Responsiveness: Theoretical and Real-world Implications

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

Study Supports Half-Dose Prasugrel for Low-Weight CAD Patients

Reduction in Platelet Reactivity with Prasugrel 5 mg in Low-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Weight Patients

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

La Eficacia del Clopidogrel se Redujo en los Diabéticos tras sufrir un IM

Efficacy of Clopidogrel Diminished in Diabetics After MI

Timing of Platelet Testing Key to Optimal Therapy After PCI for ACS

La programación de pruebas de plaqueta es fundamental para la estrategia de clopidogrel después de una ICP por ACS

PLATO Substudy: ‘Smoker’s Paradox’ Shows No Effect on Ticagrelor

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

Las Directrices Elevan el Ticagrelor a la Categoría de Antiplaquetario de 1ª Línea contra la Angina Inestable

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

Meta Análisis: Ajustar el Tratamiento según la Función Plaquetaria Mejora los Resultados

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content